PrOton Pulsed reduCed dOse Rate Radiotherapy for Recurrent CNS maligNancies Trial

Glioma Clinical Trial

— POPCORN  

Official title:

PrOton Pulsed reduCed dOse Rate Radiotherapy for Recurrent CNS maligNancies (POPCORN) Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06397560
• Other study ID #: 2022-KOT-001
• Status: Not yet recruiting
• Phase: N/A
• Start date: June 2024
• Est. completion date: June 2028

Study information

• Verified date: April 2024
• Source: Baptist Health South Florida
• Contact: Rupesh Kotecha, M.D.
• Phone: (786) 596-2000
• Email: RupeshK[@]baptisthealth.net
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this research study is to see if a specific type of radiation therapy, called "proton pulsed reduced dose rate" or "PRDR radiotherapy" has any benefits at dose levels and number of fractions thought to be acceptable in earlier research studies. The researchers want to find out what effects (good and bad) PRDR has on people with cancer in the brain called a "recurrent high-grade glioma" meaning that it grows fast, can spread quickly, and it has come back or gotten worse after being treated previously.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 28
• Est. completion date: June 2028
• Est. primary completion date: September 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Karnofsky performance status = 50

• Histologically-confirmed or radiographic evidence of recurrent / progressive glioma

• Prior treatment with radiotherapy to a minimum dose of 45 Gy

• At least 6 months or greater between completion of prior radiotherapy and enrollment in this study. If prospective participants have not passed an interval of at least 6 months, they may still be eligible if they meet one or more of the following criteria:

1. New areas of tumor outside the original radiotherapy fields as determined by the investigator.

2. Histologic confirmation of tumor through biopsy or resection AND an interval of at least 90 days between completion of radiotherapy and enrollment.

3. Nuclear medicine imaging, magnetic resonance (MR) spectroscopy, or MR perfusion imaging consistent with true progressive disease, rather than radiation necrosis obtained within 28 days of enrollment AND an interval of at least 90 days between completion of radiotherapy and enrollment.

• Must have recovered from grade 3+ toxicities of prior therapy and there must be a minimum time of 28 days prior to enrollment from the administration of any investigational agent or prior cytotoxic therapy

• Must not be pregnant (positive pregnancy test) or breastfeeding. Must agree to use of highly effective contraception during radiotherapy treatment and for an additional 6 months. Should a participant become pregnant or suspect that they are pregnant while participating in this study, they should notify the treating physician immediately.

Highly effective and acceptable forms of contraception are:

• Male condom plus spermicide

• Cap plus spermicide

• Diaphragm plus spermicide

• Copper T

• Progesterone T

• Levonorgestrel-releasing intrauterine system (e.g., Mirena®)

• Implants

• Hormone shot or injection

• Combined pill

• Mini-pill

• Patch

Individuals who meet any of the following criteria will not need contraception:

• Individuals assigned male at birth

• Amenorrhoeic for 1 year or more following cessation of exogenous hormonal treatments

• Luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels in the postmenopausal range for individuals under 50

• Radiation-induced oophorectomy with last menses > 1 year ago

• Chemotherapy-induced menopause with >1 year interval since last menses

• Surgical sterilization (bilateral oophorectomy or hysterectomy)

Exclusion Criteria:

• Two or more courses of prior radiotherapy

• Inability to undergo an MRI with contrast

• Leptomeningeal evidence of recurrent disease

• Multi-focal disease

• Any other condition that may put a participant at higher risk, at the discretion of the investigator.

Related Conditions & MeSH terms

• Central Nervous System Neoplasms
• Glioma
• Glioma, Malignant
• Recurrence
• Recurrent Glioma

Intervention

Radiation:
• PRDR
Proton pulsed reduced dose rate (PRDR) technique, to a dose of 54 Gy in 30 fractions (treatments) with proton radiotherapy. Treatments will occur once per day on consecutive weekdays.

Locations

Country	Name	City	State
United States	Lynn Cancer Institute at Baptist Health, Inc.	Boca Raton	Florida
United States	Miami Cancer Institute at Baptist Health, Inc.	Miami	Florida

Sponsors (2)

Lead Sponsor	Collaborator
Baptist Health South Florida	Ion Beam Applications SA

Country where clinical trial is conducted

United States, 

References & Publications (6)

Adkison JB, Tome W, Seo S, Richards GM, Robins HI, Rassmussen K, Welsh JS, Mahler PA, Howard SP. Reirradiation of large-volume recurrent glioma with pulsed reduced-dose-rate radiotherapy. Int J Radiat Oncol Biol Phys. 2011 Mar 1;79(3):835-41. doi: 10.1016/j.ijrobp.2009.11.058. Epub 2010 May 14. — View Citation

Bovi JA, Prah MA, Retzlaff AA, Schmainda KM, Connelly JM, Rand SD, Marszalkowski CS, Mueller WM, Siker ML, Schultz CJ. Pulsed Reduced Dose Rate Radiotherapy in Conjunction With Bevacizumab or Bevacizumab Alone in Recurrent High-grade Glioma: Survival Outcomes. Int J Radiat Oncol Biol Phys. 2020 Nov 15;108(4):979-986. doi: 10.1016/j.ijrobp.2020.06.020. Epub 2020 Jun 27. — View Citation

Dilworth JT, Krueger SA, Dabjan M, Grills IS, Torma J, Wilson GD, Marples B. Pulsed low-dose irradiation of orthotopic glioblastoma multiforme (GBM) in a pre-clinical model: effects on vascularization and tumor control. Radiother Oncol. 2013 Jul;108(1):149-54. doi: 10.1016/j.radonc.2013.05.022. Epub 2013 Jun 19. — View Citation

Kotecha R, Odia Y, Khosla AA, Ahluwalia MS. Key Clinical Principles in the Management of Glioblastoma. JCO Oncol Pract. 2023 Apr;19(4):180-189. doi: 10.1200/OP.22.00476. Epub 2023 Jan 13. — View Citation

Kutuk T, Tolakanahalli R, McAllister NC, Hall MD, Tom MC, Rubens M, Appel H, Gutierrez AN, Odia Y, Mohler A, Ahluwalia MS, Mehta MP, Kotecha R. Pulsed-Reduced Dose Rate (PRDR) Radiotherapy for Recurrent Primary Central Nervous System Malignancies: Dosimetric and Clinical Results. Cancers (Basel). 2022 Jun 15;14(12):2946. doi: 10.3390/cancers14122946. — View Citation

Saeed AM, Khairnar R, Sharma AM, Larson GL, Tsai HK, Wang CJ, Halasz LM, Chinnaiyan P, Vargas CE, Mishra MV. Clinical Outcomes in Patients with Recurrent Glioblastoma Treated with Proton Beam Therapy Reirradiation: Analysis of the Multi-Institutional Proton Collaborative Group Registry. Adv Radiat Oncol. 2020 Apr 22;5(5):978-983. doi: 10.1016/j.adro.2020.03.022. eCollection 2020 Sep-Oct. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-free survival (PFS)	PFS is defined as the duration of time from treatment start to first progressive disease (PD), date of death, or last follow-up date on which the patient was reported alive after proton PRDR reirradiation. Response to treatment will be assessed using Response Assessment in Neuro-Oncology (RANO).	3 months
Secondary	Treatment-related adverse events (AEs) assessed by Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0)	The total number of AEs considered possibly, probably, or definitely related to proton PRDR as per the CTCAE v5.0.	2 years
Secondary	Overall survival (OS)	OS is defined as the duration of time from treatment start to date of death, or last follow-up date on which the patient was reported alive after proton PRDR reirradiation.	2 years
Secondary	Grade 3 central nervous system (CNS) toxicities assessed by CTCAE v5.0	The number of CNS AEs considered possibly, probably, or definitely related to proton PRDR as per CTCAE v5.0	2 years
Secondary	Assessment of symptoms using the MD Anderson Symptom Inventory for Brain Tumors (MDASI-BT)	Symptoms will be assessed using the MDASI-BT, which is a 28-item questionnaire that asks about cancer symptoms and how the symptoms interfere with daily life. Each item is scored on a 0-10 scale (0 = best, 10 = worst), with a total score of 0-280, with a higher score indicating worse symptoms.	1 year
Secondary	Quality of life (QOL) assessed by the EuroQOL 5-dimension, 5-level (EQ-5D-5L)	QOL will be assessed using the EQ-5D-5L questionnaire. There are five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. There also is a visual analog scale asking about overall health that ranges from 0-100. Higher scores indicate better health and QOL.	1 year

External Links

•   Baptist Health Cancer Care